{
  "relevance_rule": {},
  "priority_rules": [
    {
      "priority": "Very High",
      "rule_text": "GSK-sponsored pivotal trials (usually ph 3, 2), pivotal key competitor studies that may change the SoC, ground-breaking data, high-quality ISS from key competitors or other competitors of interest that may change the SoC (GSK or competitor sponsored, well-known academic center, multiple academic centers, consortiums, key indication/s of interest). GSK- or key competitor\u2013sponsored symposia in indication/s of interest. Only Oral presentations will be considered. Secondary condition: LBA/Oral presentation that will be part of a presidential or highlighted as a news of the day, by the congress.",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "GSK-sponsored",
          "pivotal trial",
          "phase 3",
          "phase 2",
          "key competitor",
          "SoC",
          "ground-breaking",
          "ISS",
          "well-known academic center",
          "multiple academic centers",
          "consortium",
          "symposia",
          "indication of interest",
          "Oral presentation",
          "LBA",
          "presidential session",
          "news of the day"
        ],
        "categories": [
          "GSK Product",
          "Competitors",
          "Drug Class",
          "Endometrial Cancer Studies",
          "Genetic testing"
        ],
        "contextual_concepts": [
          "pivotal trial",
          "change in standard of care",
          "ground-breaking data",
          "high-quality ISS",
          "multiple academic centers",
          "presidential session",
          "highlighted news"
        ]
      },
      "exclusions": [
        "Poster",
        "e-poster",
        "Non-clinical",
        "Pre-clinical",
        "Internal only"
      ],
      "reasoning": "This rule requires both keyword and contextual understanding to identify pivotal trials, ground-breaking data, and session types. Only oral presentations are considered, making it mutually exclusive from lower priority rules that include posters."
    },
    {
      "priority": "High",
      "rule_text": "Company-sponsored pivotal trials (usually ph 3, 2) from other competitors of interest. High-quality RWE/HEOR studies from key competitors or competitors that may change the SoC (large database, indication of interest, potential to change SoC, or inform a study that can change SoC). ISS from key competitors or other competitors of interest [well-known academic center, indication of interest, multiple academic centers (>20), consortiums]. GSK- or key competitor\u2013sponsored medical education sessions on indications of interest. Any pivotal/ground-breaking company-sponsored ph 1 datasets from key competitors (assets that have not had a pivotal data readout or assets going into rare indications). Oral presentations. Poster/e-poster presentations to be considered only when it fulfils any of the above criteria.",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "company-sponsored",
          "pivotal trial",
          "phase 3",
          "phase 2",
          "key competitor",
          "RWE",
          "HEOR",
          "SoC",
          "large database",
          "ISS",
          "well-known academic center",
          "multiple academic centers",
          "consortium",
          "medical education session",
          "indication of interest",
          "Oral presentation",
          "Poster",
          "e-poster",
          "phase 1",
          "rare indication"
        ],
        "categories": [
          "Competitors",
          "Drug Class",
          "Endometrial Cancer Studies",
          "Genetic testing"
        ],
        "contextual_concepts": [
          "pivotal trial",
          "change in standard of care",
          "high-quality RWE/HEOR",
          "large database",
          "ground-breaking phase 1 data",
          "medical education session"
        ]
      },
      "exclusions": [
        "Non-clinical",
        "Pre-clinical",
        "Internal only",
        "GSK-sponsored pivotal trials (Very High)",
        "Symposia (Very High)"
      ],
      "reasoning": "This rule is hybrid as it requires both keyword matching and contextual understanding to identify pivotal trials, RWE/HEOR, and session types. Posters/e-posters are included only if they meet the criteria, making it mutually exclusive from Very High priority."
    },
    {
      "priority": "Medium",
      "rule_text": "Non-pivotal studies from key competitors. Single-center, single-country datasets from key competitors and other emerging competitors of interest. Any abstract with clinical data which do not fall under Very High/High criteria. Oral presentations. Poster or e-poster presentations. Trials in progress (TIP).",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "non-pivotal",
          "key competitor",
          "single-center",
          "single-country",
          "emerging competitor",
          "clinical data",
          "Oral presentation",
          "Poster",
          "e-poster",
          "TIP",
          "trial in progress"
        ],
        "categories": [
          "Competitors",
          "Drug Class",
          "Endometrial Cancer Studies",
          "Genetic testing"
        ],
        "contextual_concepts": [
          "non-pivotal study",
          "single-center dataset",
          "clinical data not meeting Very High/High criteria",
          "trial in progress"
        ]
      },
      "exclusions": [
        "Non-clinical",
        "Pre-clinical",
        "Internal only",
        "GSK-sponsored pivotal trials (Very High)",
        "Company-sponsored pivotal trials (High)",
        "Symposia (Very High)",
        "Medical education session (High)"
      ],
      "reasoning": "This rule is hybrid as it requires both keyword and context to identify non-pivotal studies, single-center datasets, and clinical data not meeting higher priority criteria. It is mutually exclusive from Very High and High by definition."
    },
    {
      "priority": "Low",
      "rule_text": "Non-clinical/pre-clinical studies from key competitors or other competitors of interest.",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "non-clinical",
          "pre-clinical",
          "key competitor",
          "competitor of interest"
        ],
        "categories": [
          "Competitors",
          "Drug Class",
          "Endometrial Cancer Studies",
          "Genetic testing"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "clinical",
        "GSK-sponsored",
        "pivotal",
        "symposia",
        "medical education session"
      ],
      "reasoning": "This rule is keywords-based as it can be identified by matching 'non-clinical' or 'pre-clinical' with competitor names. It is mutually exclusive from higher priority rules by definition."
    },
    {
      "priority": "Internal",
      "rule_text": "GSK-sponsored relevant abstracts (with indication of interest and keywords) excluding GSK-sponsored pivotal trials (usually ph 3, 2), pivotal key competitor studies that may change the SoC or GSK sponsored symposia or medical education session - as they are considered as Very High/High.",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "GSK-sponsored",
          "indication of interest"
        ],
        "categories": [
          "GSK Product",
          "Drug Class",
          "Endometrial Cancer Studies",
          "Genetic testing"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "GSK-sponsored pivotal trials",
        "pivotal key competitor studies",
        "symposia",
        "medical education session"
      ],
      "reasoning": "This rule is keywords-based, focusing on GSK-sponsored abstracts with relevant indications and keywords, but explicitly excluding those that fall under Very High/High priority."
    }
  ]
}